Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Stock Exchange TSE
Industry Gold
Sub-IndustryN/A
SectorBasic Materials
SymbolTSE:ARZ
CUSIPN/A
Phone+1-905-8761118
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-100.42%
Return on Equity-146.16%
Return on Assets-20.43%
Miscellaneous
EmployeesN/A
Outstanding Shares67,194,000
Market CapC$119.34
Aralez Pharmaceuticals (TSE:ARZ) Frequently Asked Questions
What is Aralez Pharmaceuticals' stock symbol?
Aralez Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ARZ."
How were Aralez Pharmaceuticals' earnings last quarter?
Aralez Pharmaceuticals Inc (TSE:ARZ) released its earnings results on Tuesday, May, 8th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.05. The firm earned $48.14 million during the quarter, compared to analyst estimates of $40.80 million. Aralez Pharmaceuticals had a negative net margin of 100.42% and a negative return on equity of 146.16%. View Aralez Pharmaceuticals' Earnings History.
When is Aralez Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Aralez Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aralez Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Aralez Pharmaceuticals' key competitors?
Some companies that are related to Aralez Pharmaceuticals include Golden Star Resources (GSC), Teranga Gold (TGZ), Argonaut Gold (AR), Perseus Mining (PRU), Perseus Mining (PRU), Sabina Gold & Silver (SBB), Gold Standard Ventures (GSV), Roxgold (ROXG), Dalradian Resources (DNA), Golden Star Resources (GSS), Atlantic Gold (AGB), Argonaut Gold (ARNGF), Avesoro Resources (ASO), Tribune Resources (TBR) and Brio Gold (BRIO).
Who are Aralez Pharmaceuticals' key executives?
Aralez Pharmaceuticals' management team includes the folowing people:
- Mr. Adrian Adams, CEO & Director (Age 67)
- Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)
- Mr. Michael Kaseta, Chief Financial Officer (Age 42)
- Dr. James Patrick Tursi, Chief Medical Officer (Age 53)
- Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68)
Has Aralez Pharmaceuticals been receiving favorable news coverage?
News headlines about ARZ stock have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a news sentiment score of 0.21 on Accern's scale. They also assigned headlines about the company an impact score of 44.66 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Aralez Pharmaceuticals?
Shares of ARZ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Aralez Pharmaceuticals' stock price today?
One share of ARZ stock can currently be purchased for approximately C$0.39.
How big of a company is Aralez Pharmaceuticals?
Aralez Pharmaceuticals has a market capitalization of C$119.34 million.
How can I contact Aralez Pharmaceuticals?
Aralez Pharmaceuticals' mailing address is 7100 West Credit Ave Suite 101, MISSISSAUGA, ON L5N 0E4, Canada. The company can be reached via phone at +1-905-8761118.
MarketBeat Community Rating for Aralez Pharmaceuticals (TSE ARZ)
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
